The use of intratympanic gentamicin is an easily performed offi ce procedure for the conservative treatment of the Meniere's disease patient who has failed medical therapy. The procedure provides excellent control for the symptom of vertigo and is one of the most successful methods in the treatment of vertigo due to inner ear disorders. Surgical ablation is no longer necessary for adequate control of vestibular symptoms and that chemical ablation/ alteration may replace the need for surgical vestibular ablation in cases of disabling Meniere's disease and other inner ear causes for peripheral vertigo.
Introduction
The healthy vestibular system at rest sends equal resting signals from each vestibular labyrinth to the brainstem. The brain interprets this symmetric input as there being no motion. Partial damage or dysfunction of labyrinth leads to decrease in the fi ring rate of impulses from the affected labyrinth. As a result of this asymmetric input from the end organs, there is vertigo. Meniere's disease, temporal bone fracture due to road traffi c accident and iatrogenic (following tympanoplasty with mastoidectomy) are the common causes of partial damage or dysfunction of labyrinth that usually results in hearing loss, tinnitus and/or vertigo in majority of patients. These symptoms cause signifi cant morbidity and disability. Usually in a few days, the brain suppresses this spontaneous fi ring and adjusts to the asymmetric input. This central compensation process usually results in relief of the patient's vertigo. For those individuals where persistent disequilibrium or recurring episodic vertigo remains after the passage of time or after treatment medically, chemical or surgical ablation should be considered. The basis for successful chemical or surgical intervention is to render the ear "stable," thus allowing central vestibular compensation to occur. This stability may result from exenteration of the offending labyrinth (labyrinthectomy), denervation of the offending labyrinth (vestibular neurectomy), or ablation of the offending labyrinth (chemical ablation). Complete removal of function from the offending labyrinth is necessary to eliminate the rotational vertigo and persisting unsteadiness and starting central compensation. Surgical elimination of vestibular function (transmastoid or transcanal labyrinthectomy), however, results in total hearing loss in the surgical ear.
During the past 30 years, considerable experience has been gained with vestibular neurectomy (by Middle fossa approach, Retrosigmoid approach or Retrolabyrinthine approach), and consensus has occurred as to the effi cacy of these techniques. Vestibular nerve section is an option for hearing preservation with good vertigo control (above A. Mahadevaiah 1 B. Parikh 2 1 Senior Consultant 90%). However, signifi cant hearing loss in such conservative surgery (Middle & posterior fossa surgery) is seen in up to 9%. Also there is considerable risk of facial nerve injury, C.S.F. leak (rare in middle fossa surgery but found in about 5% of posterior fossa surgery) and meningitis [1].
More recently, over the past 10 years, chemical labyrinthectomy has been of increasing interest to otolaryngologists. The procedure is relatively easy to perform, is accomplished in the offi ce environment, is inexpensive, and usually is not disabling. At the present time, intratympanic application of an ototoxic medication, usually gentamicin, is given in varying doses and numbers of installations. It is given to eliminate disequilibrium or to ablate this end organ. Fowler [2] in 1948 produced one of the earliest reports of the use of systemic streptomycin. In 1957, Schuknecht [3] fi rst modifi ed the delivery method and performed middle ear streptomycin perfusion for treatment of unilateral Meniere's disease. All patients had resolution of their vertigo; however, fi ve of eight suffered complete hearing loss. Inconsistent protocols and use of larger doses resulted in hearing loss and the procedure was abandoned for many years. Since then, focus has turned to the use of gentamicin due to its apparent preferential vestibulotoxic effects. Multiple studies [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] have shown intratympanic gentamicin to be a relatively safe, effective treatment for unilateral Meniere's disease.
There has been signifi cant variation in methods of administration, dose, schedule, and endpoint of therapy in order to preserve cochlear function. We hereby describe our technique of intratympanic gentamicin that have been adapted from established protocols [10, 13, 17] and modifi ed by our own experience. However we would like to re-emphasize the notation by Monsell and colleagues [21] that says, "From the standpoint of the clinical skills required by the practitioner and the potential morbidity to patients, the administration of aminoglycosides for vertigo by any route of administration should be considered as great an undertaking as surgical treatment".
Materials and methods
A retrospective study was carried out involving 364 patients who underwent intratympanic gentamicin for intractable, disabling vertigo due to labyrinthine dysfunction not resolving with adequate medical treatment during the ten-year period between March 1997 and February 2006. Diagnosis of end organ lesion is very important and was made using proper history taking, clinical examination and relevant investigations. All the patients had vertigo with hearing loss, tinnitus and aural fullness in varying amounts with a few having associated nausea and vomiting. Pure tone audiometry and cold caloric test was performed in all the patients before each injection and one month after the end of therapy. In cases with bilateral Meniere's disease ITG injection is given in the ear that has more hearing loss and tinnitus. Intratympanic gentamicin was not given in cases of vertigo due to Meniere's disease in only hearing ear. Patients with active ear discharge or tympanic membrane perforation were excluded. The parameters studied were control of rotatory vertigo (complete, partial or none), tinnitus (decrease, same or increase) and change in hearing (improvement, same or worsened depending on decrease or increase in average PTA of 10 dB).
The procedure is carried out as an outpatient visit. We don't feel it necessary to anesthetize the tympanic membrane. Patient lies in supine position, with the affected ear upwards under microscope. One ml of 40 mg/ml gentamicin is taken in a 2 mL syringe. With a 1.5-inch long 26-gauge needle, initially a puncture is made in the anteroinferior quadrant which serves as a pressure relief hole to let air out. Then the needle is inserted through the tympanic membrane into the middle ear at the level of the round window niche and gentamycin is slowly pushed fi lling the middle ear to assure placement of the drug solution against the round window. Buffered gentamicin reduces the burning sensation that patients may experience. However we use low concentrations of 2% lignocaine in subsequent injections to reduce pain if the patient complains of sting in fi rst injection. The volume injected must be adequate to bathe the round window membrane; usually 0.2 to 1 mL suffi ces. Some amount of solution may pass through the eustachian tube and some amount comes out in to the canal. The amount of gentamycin instilled is between 10 to 40 mgs, depending on individual middle ear space. The patient remains in the same position for one hour with the head turned in such a way, that the solution is concentrated at the round window. The patient is instructed to keep the ear dry and return after one week. A titration protocol was used giving 4 to 6 injections no more often than once per week and halting when some measure of vestibular function is reduced (absent response to cold caloric test or presence of spontaneous nystagmus), vertigo is controlled, or hearing worsens. A few patients with severe rotatory vertigo or patients who wanted immediate relief from vertigo were also given two injections on consecutive days for faster control of symptoms.
All patients were followed up at the end of 1st month, 3rd month and 6th month of treatment protocol. At the review the patients were assessed by clinical examination and audiometry. In most of the patients after the fi rst injection the intensity of vertigo is reduced. In post-injection period patients may feel unsteadiness for 6-8 weeks until the central compensation takes place. During that period patients are advised to take vestibule sedative drugs and to do adaptation exercises if necessary. Usually 6 injections are enough to achieve total chemical labyrinthectomy in majority of cases. If there is recurrence of vertigo, injection may be repeated once a week until total relief of vertigo is achieved.
